Richard Alan Rudick Buys 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) Stock

Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Immunic Price Performance

Shares of IMUX traded up $0.02 during mid-day trading on Wednesday, hitting $1.17. 1,185,573 shares of the company traded hands, compared to its average volume of 616,367. Immunic, Inc. has a one year low of $0.97 and a one year high of $2.11. The business has a 50-day moving average of $1.46 and a 200 day moving average of $1.35.

Analyst Ratings Changes

IMUX has been the topic of several analyst reports. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday. B. Riley began coverage on Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $28.00 target price on shares of Immunic in a research report on Tuesday, July 16th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.20.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IMUX. Vanguard Group Inc. increased its holdings in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. BVF Inc. IL bought a new stake in Immunic during the first quarter worth $11,752,000. Janus Henderson Group PLC bought a new position in Immunic during the first quarter worth about $9,266,000. Ikarian Capital LLC increased its holdings in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Immunic in the first quarter valued at about $25,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.